Tazarotene/ulobetasol

Drug Profile

Tazarotene/ulobetasol

Alternative Names: Halobetasol propionate/tazarotene; IDP-118; Tazarotene/halobetasol propionate; Ulobetasol/tazarotene

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator Dow Pharmaceutical Sciences
  • Developer Dow Pharmaceutical Sciences; Valeant Pharmaceuticals International
  • Class Antipsoriatics; Corticosteroids; Keratolytics; Nicotinic-acids; Retinoids; Small molecules
  • Mechanism of Action Retinoid X receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis

Most Recent Events

  • 26 May 2017 Chemical structure information added
  • 28 Apr 2017 Valeant intends to launch tazarotene/ulobetasol for the treatment of plaque psoriasis in the year 2018 (Valeant pipeline, October 2015).
  • 26 Apr 2017 Valeant Pharmaceuticals and Dow Pharmaceutical Sciences completes a phase III trial for Plaque psoriasis in USA (Topical) (NCT02462083)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top